retatrutide phase 2 trial results Today, we shared new data from two 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Dosage & Titration: Complete

Semaglutides 14.9% average weight loss is substantial

Its GLP-1 Patches are marketed as a simple, non-prescription way to support weight-loss goals without doctor visits or medications like Ozempic or Wegovy

Follow-ups are also ordered at your providers discretion, often at the 36-month mark to check progress, monitor side effects, or adjust dosage

Faster shipping, easier communication, clearer return processes, and reduced customs complications justify domestic sourcing preferences

Peptides for menopause-related weight work faster when triple-agonist mechanisms accelerate fat mobilization beyond what single-agonist therapies achieve

Patients should contact a medical provider if they experience severe vomiting, dehydration, persistent abdominal pain, severe constipation, symptoms of gallbladder problems, or any concerning reaction